Page results
-
UCLH is the first NHS trust to pilot a personalised educational package for patients living with stroke.
-
Our staff have rated UCLH as the top trust in England, improving on our ranking from last year when we were third best in England and top in London.
-
UCLH has declared a climate and health emergency and has published an action plan to reach net zero carbon dioxide emissions.
-
On Saturday 25 June 2022, UCLH partnered with North Middlesex University Hospital and Whittington Health to run a summer sickle cell event at Tottenham Hotspur Stadium for children and young people with sickle cell disorder.
-
Researchers at UCLH have begun a study which could set the foundations for how booster COVID-19 vaccinations are delivered in the future.
-
Nine Covid-19 research studies are already taking place at UCLH and the Trust is processing more than 30 study proposals as research efforts around the virus and pandemic are ramped up.
-
Information about preparing for and undergoing surgery at University College London Hospitals NHS Foundation Trust.
-
This page explains what patient-initiated follow-up (PIFU) involves after your treatment for endometrial (uterine or womb) cancer.
-
CAMLIS is the Royal London Hospital for Integrated Medicine (RLHIM) Complementary and Alternative Medicine Information and Library Service and is situated on the ground floor of the hospital.
-
UCLH has recruited the first patient in Europe for an early phase trial of a potential new medicine for patients that have a specific sub-type of multiple myeloma (MM), a type of bone marrow cancer.
File results
-
FOI/2023/0303 - Sexual harassment from patients towards staff in 2022
-
FOI/2023/0304 - Chronic lymphocytic leukaemia treatments
-
FOI/2023/0308 - Treatment for biologic and biosimilar products within rheumatology
-
FOI/2023/0310 - Biologic treatment/ medicines in dermatology
-
FOI/2023/0313 - Consent, confidentiality and information sharing in mental healthcare and suicide
-
FOI/2023/0315 - Menopause Lead at the Trust
-
FOI/2023/0319 - Multiple Sclerosis (MS) treatment/ medication for any diseases
-
FOI/2023/0323 - Medications/ treatment for dermatology and respiratory medicine
-
FOI/2023/0326 - Risk management system reporting rates for adverse events
-
FOI/2023/0327 - NHS long-term plan/ prevention strategy